|
1
|
Torre LA, Islami F, Siegel RL, Ward EM and
Jemal A: Global cancer in women: Burden and trends. Cancer
Epidemiol Biomarkers Prev. 26:444–457. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brenton JD, Carey LA, Ahmed AA and Caldas
C: Molecular classification and molecular forecasting of breast
cancer: Ready for clinical application? J Clin Oncol. 23:7350–7360.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Anders CK and Carey LA: Biology,
metastatic patterns, and treatment of patients with triple-negative
breast cancer. Clin Breast Cancer. 9(Suppl 2): S73–S81. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yadav BS, Sharma SC, Chanana P and Jhamb
S: Systemic treatment strategies for triple-negative breast cancer.
World J Clin Oncol. 5:125–133. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tao M, Ma D, Li Y, Zhou C, Li Y, Zhang Y,
Duan W, Xu X, Wang R, Wu L, et al: Clinical significance of
circulating tumor cells in breast cancer patients. Breast Cancer
Res Treat. 129:247–254. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Voss MJ, Möller MF, Powe DG, Niggemann B,
Zänker KS and Entschladen F: Luminal and basal-like breast cancer
cells show increased migration induced by hypoxia, mediated by an
autocrine mechanism. BMC Cancer. 11:1582011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pouysségur J, Dayan F and Mazure NM:
Hypoxia signalling in cancer and approaches to enforce tumour
regression. Nature. 441:437–443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wilson WR and Hay MP: Targeting hypoxia in
cancer therapy. Nat Rev Cancer. 11:393–410. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Semenza GL: Oxygen sensing,
hypoxia-inducible factors, and disease pathophysiology. Annu Rev
Pathol. 9:47–71. 2014. View Article : Google Scholar
|
|
10
|
Semenza GL: The hypoxic tumor
microenvironment: A driving force for breast cancer progression.
Biochim Biophys Acta. 1863:382–391. 2016. View Article : Google Scholar
|
|
11
|
Kroemer G and Pouyssegur J: Tumor cell
metabolism: Cancer's Achilles' heel. Cancer Cell. 13:472–482. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bernardi R and Gianni L: Hallmarks of
triple negative breast cancer emerging at last? Cell Res.
24:904–905. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cancer Genome Atlas N; Cancer Genome Atlas
Network: Comprehensive molecular portraits of human breast tumours.
Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stopeck AT, Brown-Glaberman U, Wong HY,
Park BH, Barnato SE, Gradishar WJ, Hudis CA and Rugo HS: The role
of targeted therapy and biomarkers in breast cancer treatment. Clin
Exp Metastasis. 29:807–819. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang GL, Jiang BH, Rue EA and Semenza GL:
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS
heterodimer regulated by cellular O2 tension. Proc Natl
Acad Sci USA. 92:5510–5514. 1995. View Article : Google Scholar
|
|
16
|
Semenza GL: Hypoxia-inducible factors:
Mediators of cancer progression and targets for cancer therapy.
Trends Pharmacol Sci. 33:207–214. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Semenza GL: Hypoxia-inducible factor 1:
Master regulator of O2 homeostasis. Curr Opin Genet Dev.
8:588–594. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ke Q and Costa M: Hypoxia-inducible
factor-1 (HIF-1). Mol Pharmacol. 70:1469–1480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Smoliga JM, Baur JA and Hausenblas HA:
Resveratrol and health - a comprehensive review of human clinical
trials. Mol Nutr Food Res. 55:1129–1141. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aggarwal BB, Bhardwaj A, Aggarwal RS,
Seeram NP, Shishodia S and Takada Y: Role of resveratrol in
prevention and therapy of cancer: Preclinical and clinical studies.
Anticancer Res. 24:2783–2840. 2004.PubMed/NCBI
|
|
21
|
Jeong SH, Song IS, Kim HK, Lee SR, Song S,
Suh H, Yoon YG, Yoo YH, Kim N, Rhee BD, et al: An analogue of
resveratrol HS-1793 exhibits anticancer activity against MCF-7
cells via inhibition of mitochondrial biogenesis gene expression.
Mol Cell. 34:357–365. 2012. View Article : Google Scholar
|
|
22
|
Kim HJ, Yang KM, Park YS, Choi YJ, Yun JH,
Son CH, Suh HS, Jeong MH and Jo WS: The novel resveratrol analogue
HS-1793 induces apoptosis via the mitochondrial pathway in murine
breast cancer cells. Int J Oncol. 41:1628–1634. 2012.PubMed/NCBI
|
|
23
|
Jeong SH, Jo WS, Song S, Suh H, Seol SY,
Leem SH, Kwon TK and Yoo YH: A novel resveratrol derivative,
HS1793, overcomes the resistance conferred by Bcl-2 in human
leukemic U937 cells. Biochem Pharmacol. 77:1337–1347. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jeong NY, Yoon YG, Rho JH, Lee JS, Lee SY,
Yoo KS, Song S, Suh H, Choi YH and Yoo YH: The novel resveratrol
analog HS-1793-induced polyploid LNCaP prostate cancer cells are
vulnerable to downregulation of Bcl-xL. Int J Oncol. 38:1597–1604.
2011.PubMed/NCBI
|
|
25
|
Jeong SH, Lee JS, Jeong NY, Kim TH, Yoo
KS, Song S, Suh H, Kwon TK, Park BS and Yoo YH: A novel resveratrol
analogue HS-1793 treatment overcomes the resistance conferred by
Bcl-2 and is associated with the formation of mature PML nuclear
bodies in renal clear cell carcinoma Caki-1 cells. Int J Oncol.
35:1353–1360. 2009.PubMed/NCBI
|
|
26
|
Jeong MH, Yang KM, Choi YJ, Kim SD, Yoo
YH, Seo SY, Lee SH, Ryu SR, Lee CM, Suh H, et al: Resveratrol
analog, HS-1793 enhance anti-tumor immunity by reducing the
CD4+CD25+ regulatory T cells in FM3A tumor
bearing mice. Int Immunopharmacol. 14:328–333. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim JA, Kim DH, Hossain MA, Kim MY, Sung
B, Yoon JH, Suh H, Jeong TC, Chung HY and Kim ND: HS-1793, a
resveratrol analogue, induces cell cycle arrest and apoptotic cell
death in human breast cancer cells. Int J Oncol. 44:473–480.
2014.
|
|
28
|
Um HJ, Bae JH, Park JW, Suh H, Jeong NY,
Yoo YH and Kwon TK: Differential effects of resveratrol and novel
resveratrol derivative, HS-1793, on endoplasmic reticulum
stress-mediated apoptosis and Akt inactivation. Int J Oncol.
36:1007–1013. 2010.PubMed/NCBI
|
|
29
|
Kim DH, Hossain MA, Kim MY, Kim JA, Yoon
JH, Suh HS, Kim GY, Choi YH, Chung HY and Kim ND: A novel
resveratrol analogue, HS-1793, inhibits hypoxia-induced HIF-1α and
VEGF expression, and migration in human prostate cancer cells. Int
J Oncol. 43:1915–1924. 2013.PubMed/NCBI
|
|
30
|
Kim DH, Kim MJ, Sung B, Suh H, Jung JH,
Chung HY and Kim ND: Resveratrol analogue, HS-1793, induces
apoptotic cell death and cell cycle arrest through downregulation
of AKT in human colon cancer cells. Oncol Rep. 37:281–288.
2017.
|
|
31
|
Tada H, Shiho O, Kuroshima K, Koyama M and
Tsukamoto K: An improved colorimetric assay for interleukin 2. J
Immunol Methods. 93:157–165. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sung B, Park S, Ha YM, Kim DH, Park CH,
Jung KJ, Kim MS, Kim YJ, Kim MK, Moon JO, et al:
Salicylideneamino-2-thiophenol modulates nuclear factor-κB through
redox regulation during the aging process. Geriatr Gerontol Int.
15:211–219. 2015. View Article : Google Scholar
|
|
33
|
Semenza GL: Hypoxia, clonal selection, and
the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol.
35:71–103. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Folkman J: Role of angiogenesis in tumor
growth and metastasis. Semin Oncol. 29(Suppl 16): 15–18. 2002.
View Article : Google Scholar
|
|
35
|
Schindl M, Schoppmann SF, Samonigg H,
Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P
and Oberhuber G; Austrian Breast and Colorectal Cancer Study Group:
Overexpression of hypoxia-inducible factor 1alpha is associated
with an unfavorable prognosis in lymph node-positive breast cancer.
Clin Cancer Res. 8:1831–1837. 2002.PubMed/NCBI
|
|
36
|
Huang M, Chen Q, Xiao J, Yao T, Bian L,
Liu C and Lin Z: Overexpression of hypoxia-inducible factor-1α is a
predictor of poor prognosis in cervical cancer: A clinicopathologic
study and a meta-analysis. Int J Gynecol Cancer. 24:1054–1064.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hubbi ME, Gilkes DM, Hu H, Kshitiz, Ahmed
I and Semenza GL: Cyclin-dependent kinases regulate lysosomal
degradation of hypoxia-inducible factor 1α to promote cell-cycle
progression. Proc Natl Acad Sci USA. 111:E3325–E3334. 2014.
View Article : Google Scholar
|
|
38
|
Forsythe JA, Jiang BH, Iyer NV, Agani F,
Leung SW, Koos RD and Semenza GL: Activation of vascular
endothelial growth factor gene transcription by hypoxia-inducible
factor 1. Mol Cell Biol. 16:4604–4613. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Carbó N, Costelli P, Baccino FM,
López-Soriano FJ and Argilés JM: Resveratrol, a natural product
present in wine, decreases tumour growth in a rat tumour model.
Biochem Biophys Res Commun. 254:739–743. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu SL, Sun ZJ, Yu L, Meng KW, Qin XL and
Pan CE: Effect of resveratrol and in combination with 5-FU on
murine liver cancer. World J Gastroenterol. 10:3048–3052. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kimura Y and Okuda H: Resveratrol isolated
from Polygonum cuspidatum root prevents tumor growth and metastasis
to lung and tumor-induced neovascularization in Lewis lung
carcinoma-bearing mice. J Nutr. 131:1844–1849. 2001.PubMed/NCBI
|
|
42
|
Marier JF, Vachon P, Gritsas A, Zhang J,
Moreau JP and Ducharme MP: Metabolism and disposition of
resveratrol in rats: Extent of absorption, glucuronidation, and
enterohepatic recirculation evidenced by a linked-rat model. J
Pharmacol Exp Ther. 302:369–373. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Garvin S, Ollinger K and Dabrosin C:
Resveratrol induces apoptosis and inhibits angiogenesis in human
breast cancer xenografts in vivo. Cancer Lett. 231:113–122. 2006.
View Article : Google Scholar
|
|
44
|
Castillo-Pichardo L, Cubano LA and
Dharmawardhane S: Dietary grape polyphenol resveratrol increases
mammary tumor growth and metastasis in immunocompromised mice. BMC
Complement Altern Med. 13:62013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bove K, Lincoln DW and Tsan MF: Effect of
resveratrol on growth of 4T1 breast cancer cells in vitro and in
vivo. Biochem Biophys Res Commun. 291:1001–1005. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jeong SK, Yang K, Park YS, Choi YJ, Oh SJ,
Lee CW, Lee KY, Jeong MH and Jo WS: Interferon gamma induced by
resveratrol analog, HS-1793, reverses the properties of tumor
associated macrophages. Int Immunopharmacol. 22:303–310. 2014.
View Article : Google Scholar : PubMed/NCBI
|
